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Abstract
Haemolysis is a very common phenomenon and is referred as the release of intracellular
components from red blood cells to the extracellular fluid. Haemolysed samples are often rejected
in clinics due to the interference of haemoglobin and intracellular components in laboratory
measurements. Plasma and serum based vibrational spectroscopy studies are extensively applied
to generate spectral biomarkers for various diseases. However, no studies have reported the effect
of haemolysis in blood based vibrational spectroscopy studies. This study was undertaken to
evaluate the effect of haemolysis on infrared and Raman spectra of blood plasma. In this study,
prostate cancer plasma samples (n=30) were divided into three groups (non-haemolysed, mildly
haemolysed and moderately hemolysed) based on the degree of haemolysis and FTIR and Raman
spectra were recorded using high throughput (HT)-FTIR and HT-Raman spectroscopy.
Discrimination was observed between the infrared and Raman spectra of non-haemolysed and
haemolysed plasma samples using principal component analysis. A classical least square fitting
analysis showed differences in the weighing of pure components in non-haemolysed and
haemolysed plasma samples. Therefore, it is worth to consider the changes in spectral features due
to haemolysis when comparing the results within and between experiments.

Keywords: Haemolysis, blood plasma, FTIR spectroscopy, Raman spectroscopy, principal
component analysis, classical least squares fitting analysis.
1. Introduction
Haemolysis (or hemolysis) refers to the breakdown of erythrocytes and resulting in the release of
intracellular components into the extracellular fluid, i.e. the plasma or serum [1] . Haemolysis is
discernible as a red colouration of the plasma or serum after centrifugation of the sample and can
occur both in-vivo and in vitro. The upper reference limit for free haemoglobin in plasma is around
20 mg/L [2]. Several factors causing in-vitro haemolysis are given in Table 1 [2]. Not all
haemolysed specimens can be associated with in-vitro haemolysis because more than 50 medical
conditions are associated with in-vivo haemolysis [3], such as cancer [4], autoimmune disorders
[5], surgery [6] etc. In-vivo haemolysis can be easily concealed by in-vitro haemolysis. In these
cases, samples haemolysed because of a medical condition may be refused because haemolysis
had been attributed to improper specimen phlebotomy, without considering the condition causing
in-vivo haemolysis [7].
In-vivo haemolysis can be distinguished from in-vitro haemolysis by estimating the concentration
of haptoglobin [8]. Haptoglobin is formed in the liver and binds to free haemoglobin released from
in-vivo lysed red cells to prevent its toxic effects [9]. The haptoglobin levels are reduced in the
presence of large amounts of free haemoglobin, a decrease in the concentration of serum
haptoglobin is the most marked laboratory indicator of in-vivo haemolysis [9]. In severe cases of
in-vivo haemolysis, haptoglobin levels may be very low or even undetectable, whereas with invitro haemolysis the concentration of haptoglobin is usually not affected [8]. However, several
studies have examined the potential of haptoglobin as a marker of in-vivo haemolysis. Varying
degrees of sensitivity and specificity for haptoglobin have been shown depending on the cutoff
concentration used. One study used a haptoglobin cutoff of less than 25 mg/dL and demonstrated
83% sensitivity and 96% specificity for intravascular haemolysis [10]. Another used a haptoglobin
cutoff of less than 28 mg/dL and noted 91.8% sensitivity and 98.4% specificity for intravascular
haemolysis [11]. On the other hand, decreased levels of haptoglobin can occur in the absence of
haemolysis, due to the liver cirrhosis, disseminated ovarian carcinomatosis, pulmonary
sarcoidosis, and elevated oestrogen states [9].

In general, there is no gold standard test to confirm in-vivo haemolysis, and most often labs rely
on other clinical factors (e.g. increased reticulocyte count and decreased haptoglobin) and
correlation with other laboratory markers (e.g., complete blood count, lactate dehydrogenase and
indirect bilirubin) in addition to a patient’s history [2,9].
Many laboratory chemistry tests depend on the evaluation of light that passes through a sample,
and therefore haemolysed blood can interfere with these tests, as the red colour of haemoglobin
can interfere with the absorption of light as it passes through a haemolysed sample [12]. In
spectrophotometric assays, the absorption peak of oxyhaemoglobin lies between 531 and 543 nm.
This absorption peak is relatively broad so haemolysis intervenes over many wavelengths that are
used for the quantification of analytes [12]. Haemolysis also interferes with laboratory tests by
releasing analytes into the serum or plasma that are elevated in concentration within the red blood
cells compared to serum or plasma, thereby giving false concentrations of measured analytes [13].
The application of vibrational spectroscopy (infrared and Raman spectroscopy) to generate
spectral biomarkers of disease using biofluids such as plasma or serum is gaining increased focus.
Infrared spectroscopy is based on the absorption of infrared radiation by the sample under study
and the fact that molecules absorb specific frequencies of the incident light which are characteristic
of their structure. Raman spectroscopy is based on inelastic scattering of monochromatic light,
usually from a laser source. Many articles have been published reporting the use of Fourier
Transform Infrared (FTIR) and Raman spectroscopy with serum and/or plasma as non-invasive
diagnostics for various diseases, including cancers [14–17]. Despite haemolysis being very
common in practice, no spectroscopic study has examined its effects on spectral markers and the
concentration of analytes.
This study was undertaken to investigate the effect of haemolysis on Raman and FTIR spectra of
plasma in prostate cancer patient plasma samples (n = 30). A combination of ultraviolet (UV)Visible, high throughput (HT) - Raman and HT-FTIR spectroscopies were used to evaluate the
spectral content of both haemolysed and non-haemolysed plasma. Significant spectral differences
were observed in the infrared and Raman spectra of non-haemolysed and haemolysed plasma
samples. The acquired FTIR and Raman spectra were also analysed by principal component
analysis (PCA) and classical least squares (CLS) fitting analysis in the MATLAB environment.

The CLS fitting analysis was employed to estimate the changes in the weighting of various analytes
in non-haemolysed and haemolysed plasma samples.
2. Experimental section
2.1. Ethical approval
Ethical approval was awarded by the Technological University Dublin Research Ethics Committee
for the collection of blood samples from healthy donors. The prostate cancer patients used in this
study were recruited from the Cancer Trials Ireland (formerly All Ireland Cooperative Oncology
Research Group, ICORG) trial 08−17 which is entitled “A Prospective Phase II Dose Escalation
Study Using intensity modulated radiotherapy (IMRT) for High Risk N0 (cancer has not spread to
nearby lymph nodes) M0 (or elsewhere in the body) Prostate Cancer (NCT00951535)”. The
patients were recruited for a translational study on vibrational spectroscopy for monitoring
radiation therapy response [18]. The translational research study was approved by the St Luke’s
Radiation Oncology Network Research Ethics Committee and all research was performed in
accordance with relevant guidelines and regulations. Informed consent was obtained from all
participants. Fresh whole blood was drawn into Li-heparin tubes at St. Luke`s Radiation Oncology
Network, St. Luke’s Hospital (SLRON SLH), in Dublin, and were coded before being transferred
to the Technological University (TU) Dublin laboratory. Plasma from prostate cancer patients were
used to study the effect of in-vivo haemolysis on Raman and FTIR spectra of blood plasma. The
clinical characteristics of prostate cancer patients are detailed in Table 2. Plasma from male healthy
donor (age, 50 years) was used to study the effect of in-vitro haemolysis on Raman spectra of
blood plasma.
2.2. Plasma isolation
Plasma was isolated from these blood samples by centrifugation at 3500 g for 5 minutes at 180C.
The samples were subsequently stored at -800C prior to FTIR and Raman acquisition.
2.3. Haemoglobin isolation

A volume of 1ml of whole blood sample was centrifuged at 3500 g for 5 minutes to remove plasma.
The pelleted red blood cells (RBCs) was purified by washing with phosphate buffer saline (PBS)

for at least three times. The residual PBS was removed by centrifugation at 3500 g for 1 minute .
After purification, deionised water was added to the RBCs and sonication was performed for 30
sec to rupture the RBCs. Then, the diluted haemoglobin was further centrifuged at 3500 g for 5
minutes to remove RBC membrane. The isolated diluted hemoglobin sample was stored at -800C
before Raman measurements.
2.4. Ultraviolet - visible spectroscopy

UV-visible spectroscopy is generally used in analytical chemistry for the quantitative
determination of various analytes. UV-visible spectroscopy uses light in the visible and adjacent
ranges.
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spectrophotometrically (Perkin Elmer Lambda 900) with water as a blank. Thirty microliters of
plasma samples were deposited on the quartz microsample cell with 0.1mm pathlength and the
absorbance at 414 nm were used to determine the haemolysis in the sample. The concentration of
haemoglobin in plasma was determined using the Beer-Lambert law.
2.5. FTIR spectroscopy
The sample preparation and acquisition methodology for FTIR spectra was detailed in our previous
paper [18]. Briefly, plasma samples stored at -80° C were thawed at room temperature and were
diluted threefold in physiological water. A volume of 4 μL diluted plasma sample was deposited
on a 384-well silicon plate (Bruker Optics GmbH, Ettlingen, Germany), and air-dried at room
temperature. For each sample, 10 spots were used giving 10 instrumental replicates. The plate was
then inserted into a high-throughput module (HTS-XT, Bruker Optics GmbH) attached to an FTIR
spectrometer (Tensor 27, Bruker Optics GmbH). FTIR spectra were acquired in the transmission
mode using the OPUS v6.5 software (Bruker Optics GmbH) in the wavenumber range from 4000
to 400 cm−1, using a spectral resolution of 4 cm−1 and 32 co-additions. FTIR spectra were then
subjected to a quality test (OPUS v6.5) and details of this test are fully described in reference [19,
20]. Spectra that passed the quality test were pre-processed and processed in the wavenumber
range from 800 to 4000 cm−1.

2.6. Raman spectroscopy

Raman spectra from liquid plasma samples were recorded using an in house developed HT-Raman
spectroscopy method [17]. Briefly, 20 µl of liquid plasma samples were deposited on a cover glass
bottomed 96 well plate (MatTek corporation) and Raman spectra of the plasma samples were
acquired using a 785nm laser focused through a 10x objective (N.A. 0.25). Spectra were recorded
using a diffraction grating ruled with 300 lines/mm giving a spectral resolution of ~2.1cm-1.
Spectra were recorded automatically from each well where the spectrometer was programmed
using an in-house developed high throughput macro template. Each spectrum was acquired over
the region from 400 –1800 cm-1. Ten spectra were recorded from each sample for each patient with
a 20 s x 2 integration time. Multiple wavenumber calibration spectra of 1,4-Bis (2-methylstyryl)
benzene and intensity calibration spectra of National Institute of Standards and Technology (NIST)
Standard Reference Material (SRM) no. 2241 were recorded along with each sample acquisition
and used in spectral post-processing.
2.7. Pure molecular reference species recording
All pure molecular references species (Table 3) were purchased from Sigma Aldrich. These
molecular species include proteins, lipids and other analytes which are usually found in the blood
plasma. Moreover, previous other studies also reported the variations in most of these molecular
species due to the effect of haemolysis [13, 21–23]. Additionally, molecular reference species of
lipids and fatty acids were included to study their interference in the plasma spectra due to in-vivo
haemolysis. More details of these pure molecular reference species are provided in supplementary
material.
Approximately 1–2 mg of each lyophilised analyte or 10 µL of liquid analyte was deposited on a
calcium fluoride slide and Raman spectra were recorded with a 785 nm laser excitation. The laser
was focused through a 10× objective (N.A. 0.25) using a diffraction grating ruled with a grating
of 300 lines per mm. Five spectra per sample were recorded for the acquisition time of 10 seconds
and 2 accumulations. FTIR spectra of all analytes were recorded using Attenuated total reflectance
(ATR)-FTIR (Perkin Elmer). Approximately 1 mg of lyophilised analyte or 5 µL of liquid analyte
(allowed to dry at room temperature) was placed on the ATR crystal (Diamond / Zinc Selenide
with refractive index 2.4) and FTIR spectra were acquired in the transmission mode using the

spectrum software and using the following conditions: wavenumber range from 4000 to 700 cm−1,
spectral resolution of 4 cm−1, and each spectrum was averaged over 8 scans.
2.8. Data analysis
All spectral processing procedures were carried out using MATLAB (R2017a; Mathworks Inc.,
Natick, MA), along with in-house developed algorithms and procedures available within the PLS
Toolbox (v 8.0.2, Eigenvector Research Inc., Wenatchee, MA).
2.8.1. Pre-processing
Pre-processing of FTIR spectra includes baseline correction, calculation of second derivative
spectra and vector normalisation. Baseline correction was performed using the rubberband
baseline subtraction [24]. Second derivative spectra were calculated using Savitsky-Golay
algorithm [25] and a window length of 9 points. All spectra were standardized using vector
normalization before analysis.
The acquired Raman spectra were wavenumber calibrated relative to an in-house standard of 1,4Bis (2-methylstyryl) benzene using in-house developed calibration procedures [26] and the
instrument response correction was performed using the spectrum of NIST Standard Reference
Material (SRM) no. 2241, according to the method described [27]. Briefly, SRM 2241 emits a
broadband luminescence spectrum when illuminated with 785 nm Raman excitation laser. The
shape of this luminescence spectrum is represented by a polynomial expression that relates the
relative spectral intensity to the Raman shift. This polynomial along with a standard luminescence
spectrum can be employed to determine the spectral intensity-response correction, which is unique
to each Raman system. The derived instrument intensity response correction can be used to obtain
Raman spectra that are corrected for instrument dependent artifacts [27]. The wavenumber and
instrument response corrected Raman spectra were smoothed using a Savitzky-Golay filter. The
background and baseline correction were performed using Extended Multiplicative Scattering
Correction (EMSC). Then, spectra were standardized using vector normalization. An example of
intensity corrected, and pre-processed liquid plasma spectrum is shown in Figure 1.
2.8.2. Multivariate analysis
Pre-processed FTIR and Raman spectra were further processed with PCA and CLS fitting analysis.

2.8.2.1. PCA
PCA was performed with the similar approach as described earlier [18]. In brief, PCA is a
commonly used method for multivariate data compression and visualization. It describes data
variance by identifying a new set of orthogonal features, called principal components (PCs).
2.8.2.2. CLS fitting analysis
In this study, classical least squares (CLS) fitting analysis was performed on the second derivative
FTIR spectra and vector normalised Raman spectra to estimate the relative fraction (a proxy for
concentration) of reference spectra (of pure components) within a sample spectrum. The use of
CLS fitting analysis to determine the relative concentrations of cellular components have been
reported previously [28,29]. The pure components used in this study are given in Table 2. CLS is
an exploratory method that assumes that any complex spectrum is the linear sum of contributions
from spectra of pure components that contribute to the spectrum as described in the following
equation [30]:
𝑆 = 𝑎! 𝐶! + 𝑎" 𝐶" + ⋯ + 𝐸
Where S represents a sample spectrum, a1 and a2 are component spectra and C1 and C2 are the
weights or concentrations assigned to each component spectrum. In the case of a Raman or FTIR
spectrum, not all contributing pure components are known. Therefore, an error or residual, E, in
the fitting estimation will be observed that will equate to the difference between the sample
spectrum and the sum of the component spectra:
𝐸# = 𝑆# − (𝑎!# 𝐶! + 𝑎"# 𝐶" + 𝑎$# 𝐶$ )
Where E

j

is the error associated with the intensity of the j-th wavenumber. Applying CLS

minimizes the error in fitting the sample spectrum, S. The minimum error occurs when the
differential of the sum of squared errors is equal to zero.
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Differentiating with respect to each of the component will give the above equation and using the
method of simultaneous equations the weighting components can be calculated. Alternatively

using matrix methods and the matrix of weighting coefficients can be solved for using the
following equation.
[𝐶 ] = [𝐴] [𝑎]0 [𝑎𝑎0 ],!
where a is a component of sample spectra.

3. Results and discussion
3.1. Haemoglobin spectra

Three different types of plasma samples were observed in our plasma biobank (Figure 2). The
normal plasma sample is clear and pale yellow in colour (Figure 2C). The haemolysed plasma
sample is pale red in colour (Figure 2A) and the lipemic plasma sample is white in colour (Figure
2B). Lipemia is a turbidity of the sample caused by aggregation of lipoprotein particles 31.
Figure 3 shows a representative UV-Visible absorption spectrum of haemoglobin recorded from
the haemolysed prostate cancer plasma sample. The absorption bands at 414 cm-1, 546 cm-1 and
571 cm-1 indicates the presence of oxyhaemoglobin. Figure 4 shows the FTIR absorption spectrum
recorded from the haemoglobin standard (Sigma Aldrich). As haemoglobin is a protein, the FTIR
absorption spectrum contains amide I band (between 1600 and 1700 cm-1), amide II band (between
1510 and 1580 cm-1), amide III band (between 1300 and 1400 cm-1), amide A band (between 3300
and 3500 cm-1). Figure 5A, 5B and 5C shows the Raman spectra recorded from the lyophilised
haemoglobin standard, diluted haemoglobin standard and the haemoglobin isolated from blood
respectively. The Raman spectra acquired from the lyophilised haemoglobin standard gave a
fluorescence signal because of the bright red colour of haemoglobin. However, the fluorescence
signal was not observed in Raman spectra from diluted and isolated haemoglobin. This might be
due to the reduction of red colour of haemoglobin by diluting with deionised water. The Raman
spectrum from diluted haemoglobin and isolated haemoglobin contains protein related bands at
750 cm-1, 1002 cm-1, 1035 cm-1, 1125-1150 cm-1, 1210 cm-1 (phenylalanine), 1170 cm-1 (tyrosine),
1035 cm-1, 1230 cm-1 -1300 cm-1 (Amide III), 1480 cm-1 – 1580 cm-1 (Amide III), and 1600 1660 cm-1 (phenylalanine, tyrosine, Amide I). These bands are more prominent in diluted
haemoglobin compared to isolated haemoglobin from RBC.

3.2. Plasma categorization based on haemolysis

Specimens were categorized according to the haemoglobin concentration into three groups:
•

Group 1 (0 - 0.1g/L), non-haemolysed (n=12);

•

Group 2 (0.20 - 0.50 g/L), mildly haemolysed (n=10);

•

Group 3 (0.50 - 0.93 g/L), moderately haemolysed (n=8).

The results were analysed to determine if non-haemolysed, mildly haemolysed and moderately
haemolysed samples had a significant impact on the analyte concentrations estimated by CLS
fitting analysis. The median free haemoglobin concentrations for groups 1, 2 and 3 were measured
as 0.02, 0.44 and 0.71 g/L respectively. At free haemoglobin concentration of 0.2 g/L, haemolysis
was visible by the light red colour of the plasma. The haemolysed plasma samples appeared to be
more turbid compared to non-haemolysed plasma samples. The increase in turbidity in haemolysed
samples may be due to hyperlipidemia. It has been reported that hyperlipidemia is associated with
increased haemolysis [32]. It is postulated that enhanced lipid concentration changes the lipid
content of the erythrocyte membrane, resulting in increased erythrocyte fragility and subsequent
leakage of cellular content into the plasma [32].
3.3. Comparison of spectral features of non-haemolysed and haemolysed plasma samples

Figure 6 shows the mean FTIR spectra of non-haemolysed and haemolysed plasma obtained from
the prostate cancer patients. To explain the differences between each group, difference spectra
were computed by subtracting the spectra of haemolysed plasma samples from the spectra of nonhaemolysed plasma samples. The first panel in Figure 7 shows the difference FTIR spectra
obtained from moderately haemolysed and mildly haemolysed plasma samples. The second panel
shows the difference FTIR spectra obtained from mildly haemolysed and non-haemolysed plasma
samples and the third panel shows the difference FTIR spectra obtained from moderately
haemolysed and non-haemolysed plasma samples.
Major differences were observed in the region around 1550 cm-1 (Amide II) [20] , 1660 cm-1
(Amide I) [20], 1740-1760 cm-1 (stretching vibrations of (C=O) of fatty acids, triglycerides, and

cholesterol esters) [33], 2800-2950 cm-1 (stretching vibrations of (CH2/CH3) of lipids fatty acids,
triglycerides and proteins) [33], 3300 cm-1 (Amide A) [20] and 3400-3600 cm-1 (OH stretch) [34]
between non-haemolysed and haemolysed plasma groups. The increase in fatty acids (1740-1760
cm-1), lipids (2800-2960 cm-1) and OH stretch (3400-3600 cm-1) and the decrease in glycogen,
nucleic acids (1000-1100 cm-1) [33,35], amide II (1550 cm-1), amide I (1660 cm-1) and amide A
(3300 cm-1) were observed with an increase in haemolysis. The decrease in amide II, amide I and
amide A suggests the decrease in protein content with an increase in haemolysis and the increase
in fatty acids, lipids and OH stretch suggest the increase in lipids with an increase in haemolysis.
The increase in lipids and fatty acids in haemolysed plasma samples may indicate in-vivo
haemolysis [32]. As mentioned earlier, the haemolysed plasma specimens appeared to be more
turbid compared to non-haemolysed plasma samples due to hyperlipidemia. The increase in lipid
concentration with an increase in haemolysis has also been reported previously [32].
Figure 8 shows the mean Raman spectra of non-haemolysed and haemolysed plasma obtained
from the prostate cancer patients. The first panel in Figure 9 shows the difference Raman spectra
obtained from moderately haemolysed and mildly haemolysed plasma samples. The second panel
shows the difference Raman spectra obtained from mildly haemolysed and non-haemolysed
plasma samples and the third panel shows the difference Raman spectra obtained from moderately
haemolysed and non-haemolysed plasma samples. Major intensity related differences were
observed in the region around 877 cm−1, 881 cm−1, 1006 cm−1, 1085 cm−1, 1210 cm−1, 1270 cm−1,
1302 cm−1, 1345 cm−1, 1450 cm−1, 1528 cm−1, and 1660 cm−1. The bands corresponding to
phenylalanine (1006 cm−1 and 1210 cm−1) [36] increased with increase in haemolysis. The increase
in the amide linkage bands (1302, 1340 cm−1) [37] was observed in non-haemolysed plasma
compared to haemolysed plasma. The CH2 deformation (1340 cm−1) [37] bands were decreased
with increase in haemolysis. The bands corresponding to cholesterol (881cm−1 and 1450 cm−1) [38]
and triglycerides (877 cm−1, 1270 cm−1 and 1450 cm−1) [38] were increased with increase in
haemolysis. This increase in lipid profile with an increase in haemolysis was also observed in the
FTIR spectral analysis.

3.4. Multivariate analysis
3.4.1. PCA

PCA was performed on second derivative of the mean FTIR spectra by patient, using the
wavenumber range of 4000-800 cm-1. PCA was carried out with 10 PCs and the first 2 PCs
accounted for ∼91% of the total percentage variance. The first two PCs were used to visualize the
classification between the groups. The scatter plot revealed three well differentiated clusters
between the analysed groups (Figure 10A).
The PCA analysis showed clear discrimination between the FTIR spectra of non, mildly and
moderately haemolysed plasma samples. PC1 showed the discrimination between the FTIR spectra
of non and mild haemolysed plasma samples and moderate haemolysed plasma samples. PC1
shows positive band associated with proteins (1657 cm-1) in the moderately haemolysed plasma
group and negative bands associated with glycogen, nucleic acids (1040 cm-1, 1063 cm-1, 1090 cm1

and 1120 cm-1), lipids, triglycerides and fatty acids (1744 cm-1, 2853 cm-1, 2926 cm-1 and 2963

cm-1) in the non and mildly haemolysed plasma groups. PC2 showed the discrimination between
the FTIR spectra of non-haemolysed and mild haemolysed plasma samples. PC2 shows positive
bands at 1040 cm-1, 1120 cm-1 and 1640 cm-1 in the mildly haemolysed plasma group and negative
bands at 1744 cm-1, 2853 cm-1, 2926 cm-1 and 2963 cm-1 in the non-haemolysed plasma group.
The positive bands in PC2 are assigned to glycogen, RNA and protein and negative bands are
assigned to lipids, triglycerides and fatty acids. The PCA analysis showed the main discriminating
features between non-haemolysed and haemolysed plasma samples are related to glycogen, nucleic
acids, proteins, fatty acids, triglycerides and lipids. The FTIR difference spectrum analysis also
showed similar discriminating spectral features between the non-haemolysed, mild and moderate
haemolysed plasma samples.
Figure 11 shows the results of PCA analysis performed on the vector normalised Raman spectra
of non-haemolysed and haemolysed plasma groups. The first two PCs accounted for ∼58% of the
total percentage variance and the scatter plot revealed overlapped clusters between the analysed
groups. Only PC1 showed the discrimination between the Raman spectra of non and mild
haemolysed plasma samples and moderate haemolysed plasma samples. PC1 has positive bands
at 1003 cm-1, 1080 cm-1, 1155 cm-1, 1430 cm-1 and 1650 cm-1 in the non and mildly haemolysed

plasma groups and negative bands at 1007 cm-1, 1210 cm-1, 1260 cm-1, 1346 cm-1 1460 cm-1 and
1660 cm-1 in the moderately haemolysed plasma group. The positive bands assigned to proteins,
amino acids, carotenoids and lipids, and negative bands related to amino acids, proteins and lipids.
The PCA showed proteins and lipids are the major discriminating features between the Raman
spectra of plasma from non and mildly haemolysed versus moderately haemolysed patient groups.
Similar discriminating features were also observed in the difference spectrum analysis of Raman
spectra from non-haemolysed and haemolysed plasma groups.
3.4.2. CLS fitting analysis

CLS fitting analysis was performed to examine the alterations in the weighting of analytes in
Raman and FTIR spectra with variable haemolysis. Significance testing was performed on the
identified plasma analytes using two-tailed students t-tests with the significance level of p≤0.05,
0.01 and 0.001. Figure 12 shows the results of CLS fitting analysis performed on the nonhaemolysed and haemolysed plasma second derivative FTIR spectra. In particular a differentiation
in the weighting of albumin, phosphatidyl-ethanolamine (p-ethanolamine), uric acid, ceramide,
thymidine, ubiquitin, triglyceride, Interleukin-6 and Interleukin-8 were observed between the
FTIR spectra of non-haemolysed and haemolysed plasma samples. An increase in the weighting
of albumin, ceramide, uric acid and ubiquitin was observed with an increase in haemolysis.
Conversely a decreased weighting of thymidine and interleukin-6 was observed with increase in
haemolysis. Similarly, a decreased weighting of triglyceride was observed in the haemolysed
samples compared to non-haemolysed plasma samples. The increase in ceramide and pethanolamine suggests an increase in lipid concentration with increase in haemolysis. An increased
concentration of albumin [13] and ubiquitin [39] with an increase in haemolysis has also been
reported previously.
Figure 13 shows the results of CLS fitting analysis performed on the Raman spectra from nonhaemolysed and haemolysed plasma. Significant differences were observed in the weighting of
uric acid, albumin, insulin, p-ethanolamine, creatinine, interleukin-6, RNA, urea and thymidine.
A decreased weighting for uric acid and urea was observed with increase in haemolysis. A
decreased concentration of uric acid with increase in haemolysis has also been reported previously
[21] and may arise from a premature decomposition of haemoglobin [21]. Conversely an increased

weighting of RNA and Interleukin-6 was observed with increase in haemolysis. Kirschner et al.
reported an increase in the micro RNA levels in haemolysed plasma specimens [23]. The weighting
of insulin within Raman spectra was decreased in mildly haemolysed samples and increased in
moderately haemolysed plasma samples. The weighting of albumin and creatinine was decreased
in moderately haemolysed samples compared to non and mildly haemolysed plasma samples.
Variations in the weighting of albumin, uric acid, p-ethanolamine, interleukin-6 and thymidine
were observed in both FTIR and Raman spectra of non-haemolysed and haemolysed plasma
samples. Increased weighting of p-ethanolamine was observed in both FTIR and Raman spectral
analysis. The FTIR spectral analysis showed an increased weighting of albumin with an increase
in haemolysis but a slightly decreased level of albumin was observed in the Raman spectra of the
moderately haemolysed plasma samples. A decreased weighting of uric acid, thymidine and
interleukin-6 was observed in the FTIR spectral analysis with an increase in haemolysis.
Conversely, an increased weighting of uric acid, thymidine and interleukin-6 levels were observed
in the Raman spectral analysis. The differences in the CLS fitting analysis results of FTIR and
Raman spectra may be due to the employment of different pre-processing and sample preparation
methods. Second derivative FTIR spectra were used in this analysis, second derivative spectra
allow more distinct identification of small and adjacent lying absorption peaks which are not
clearly visible in the original spectrum. The FTIR spectra were recorded from diluted and dried
plasma samples and Raman spectra were recorded from liquid plasma samples. Differences in the
sample preparation methods might also affect the identification of plasma analytes. However,
further studies would be required to confirm the variation in plasma analytes due to the different
sample preparation methods.
4. Interpatient variability
The above studies were carried out on plasma samples obtained from various prostate cancer
patients. To avoid any interpatient variability, plasma from a healthy control subject was spiked
with increasing concentrations of diluted haemoglobin (extracted from whole blood), 0.44 g/L
(mildly haemolysed), 0.93 g/L (moderately-haemolysed) and 1.31g/L (grossly-haemolysed).
Figure 14 shows the mean spectra of non-haemolysed and in-vitro haemolysed plasma samples.
Intensity related differences were observed across the spectra in the analysed plasma groups. A
decrease in the bands around 1007 cm-1, 1450 cm-1 and 1660 cm-1 were observed with an increase

in in-vitro haemolysis. These spectral features were increased with an increase in haemolysis in
the Raman spectra of plasma from prostate cancer patients and could originate in in-vivo
haemolysis or interpatient variability. Figure 15 shows the PCA scatter plot for non-haemolysed
and in-vitro spiked-haemolysed plasma samples. The first two PC’s accounted for ∼25% of the
total percentage variance and the scatter plot revealed overlapped clusters between the analysed
groups. This suggests that there are no significant discriminating spectral features between the
non-haemolysed and in-vitro haemolysed plasma specimens.
The CLS fitting analysis performed on the in-vitro haemolysed plasma samples showed
differences in the weighting of uric acid, albumin, insulin, p-ethanolamine, Interleukin-6, RNA,
urea and thymidine (Figure 16). A decrease in insulin concentration was observed with an increase
in haemolysis. This might be attributable to the previously observed release of proteolytic enzymes
during hemolysis that destroys small peptides such as insulin, gastrin etc [22]. However, this trend
was not observed in prostate cancer plasma samples. The increased concentration of urea in
haemolysed samples was reported previously [40] and this effect might be due to the cellular
release of urea into plasma during haemolysis [40]. However, in this study, the concentration of
urea was increased gradually from non-haemolysed through mildly haemolysed up to moderately
haemolysed samples and then decreased in grossly haemolysed plasma samples. Conversely, a
decreased weighting of urea was observed in prostate cancer plasma samples with an increase in
haemolysis. The decreased levels of uric acid [13], creatinine [13], insulin [22] and increased levels
of urea [40], micro RNA [23] and interleukins [41] were reported with an increase in haemolysis.
Similar trends were observed in this study up to moderately haemolysed samples but a deviation
in this trend was observed in grossly haemolysed samples. This might be due to dilution or to
interference from the bright red colour of haemoglobin as more haemoglobin was added to the
plasma to produce the grossly haemolysed plasma sample. This results in dilution and alteration
of analytes present in the plasma sample. Previous studies have also reported variations in severely
haemolysed plasma samples due to dilution [13, 40].
The weighting of uric acid, Interleukin-6 and RNA were consistent in both in-vitro haemolysed
and prostate cancer plasma samples and the weighting of urea, insulin, p-ethanolamine, thymidine
and creatine were inconsistent between the in-vitro and prostate cancer plasma samples. Consistent
weighting of pure components in in-vitro haemolysed samples and prostate cancer haemolysed

plasma samples suggests the interference of haemoglobin colour and intercellular components of
RBC in the weighing of plasma analytes. Inconsistent weighting of pure components in in-vitro
haemolysed and prostate cancer haemolysed plasma samples might be due to in-vivo haemolysis
or due to the development of cancer.
5. Conclusions

Haemolysis, in-vitro or in-vivo, can affect the concentration of analytes present in the blood
plasma and serum. Haemolysis can interfere in the quantification of several analytes in three
different ways. The first one is the interference of the red coloration of haemoglobin with the
absorption of light as it passes through a sample. The second interference is by releasing analytes
into the serum or plasma that are in high concentration within the red blood cells and the third
interference is by increasing lipid and fatty acid concentration in in-vivo haemolysis. Many studies
have reported the interference of haemoglobin in various biochemical assays, including UV-visible
spectroscopy. This study aimed to investigate the changes in the IR and Raman spectra of nonhaemolysed and haemolysed plasma samples. The mean spectra showed more changes in the FTIR
spectral features of non-haemolysed and haemolysed patient plasma groups compared to the
Raman spectral features. The increased haemolysis with an increase in the lipid content suggests
an in-vivo haemolysis in the prostate cancer plasma samples. The PCA analysis performed on
FTIR spectra showed a good separation of the plasma groups compared to the PCA performed on
Raman spectra. This suggest that FTIR spectroscopy is a preferred method for the analysis of
haemolysed samples. Finally, the CLS fitting analysis suggested significant alterations in the
weighing of analytes in FTIR and Raman spectra of non-haemolysed and haemolysed patient
plasma groups. The Raman spectroscopy study on in-vitro haemolysed samples showed minor
changes in the spectral features of non-haemolysed and haemolysed plasma specimens and CLS
fitting analysis showed similar changes in the weighting of some pure components as observed in
the Raman spectra of plasma from prostate cancer patients.
This study suggests that the FTIR spectra show more significant changes in the spectral features
and in the weighting of pure components due to haemolysis compared to the Raman spectra.
However, further FTIR studies should be performed on in-vitro haemolysed samples to confirm
these results. Both in-vitro and in-vivo haemolysis is a common phenomenon and rejecting these

samples could limit the diagnostic performance of Raman and FTIR spectroscopy. However, when
including haemolysed samples in clinical spectroscopy studies, it is important to consider any
changes in FTIR and Raman spectral features due to haemolysis when comparing results within
and between experiments. Differences in the spectral features due to haemolysis will be observed
within the patient group but most likely, these differences will be minor when compared between
patient groups, for example control and cancer cases. However, further studies are needed to
confirm this.
This is the first study to report the effect of haemolysis on infrared and Raman spectra of blood
plasma. This study was performed on a limited sample set and validation of these results on a
larger cohort will be necessary to confirm the effect of in-vitro and in-vivo haemolysis on FTIR
and Raman spectra of blood plasma. Future work should also involve biological assays showing
proteins, lipids, circulating nucleic acids and other analyte levels to corroborate the findings of the
CLS fitting analysis.
Funding: This research was funded by an Irish Research Council Postgraduate Award, COST
Action (BM1401) Short Term Scientific Mission Award, Irish Research Council-Ulysses Award
(Grant Number PJ29007), EU FP7 Network of Excellence DoReMi (Grant Number 249689) and
Science Foundation Ireland (11/RFP.1/BMT/3317).
Acknowledgements: Cancer Trials Ireland acted as sponsor for the CTRIAL-IE (ICORG) 08-17
study, providing project management, protocol development and monitoring, patient information
leaflet and CRF development, ethics application and amendments. The authors are very grateful
to the patients who participated in the CT-IE 08-17 study and donated blood samples for this
translational research study.

Conflicts of interest: The authors declare no conflicts of interest.

References
(1)

Lippi, G., Blanckaert, N., Bonini, P., Green, S., Kitchen, S., Palicka, V., Vassault, A. J.,
Plebani, M. Haemolysis: An Overview of the Leading Cause of Unsuitable Specimens in
Clinical Laboratories. Clinical Chemistry and Laboratory Medicine. 2008, 46(6), 764-72.

(2)

Thomas, K. L. Haemolysis as Influence and Interference Factor. J. Int. Fed. Clin. Chem.
Lab. Med. 2002, 13 (4), 95–98.

(3)

Carraro, P., Servidio, G., Plebani, M. Hemolyzed Specimens: A Reason for Refection of a
Clinical Challenge? Clin Chem. 2000, 46 (2), 306–307.

(4)

Rytting, M., Worth, L., Jaffe, N. Hemolytic Disorders Associated with Cancer. Hematol
Oncol Clin North Am. 1996, 10 (2), 365–376.

(5)

Go, R. S., Winters, J. L., Kay, N. E. How I Treat Autoimmune Hemolytic Anemia. Blood.
2017, 129(22), 2971-2979.

(6)

Vercaemst, L. Hemolysis in Cardiac Surgery Patients Undergoing Cardiopulmonary
Bypass: A Review in Search of a Treatment Algorithm. J. Extra. Corpor. Technol. 2008,
40(4), 257–267.

(7)

Howanitz, P. J., Lehman, C. M., Jones, B. A., Meier, F. A., Horowitz, G. L. Practices for
Identifying and Rejecting Hemolyzed Specimens Are Highly Variable in Clinical
Laboratories. Arch. Pathol. Lab. Med. 2015, 139(8), 1014-9.

(8)

Lippi, G., Cervellin, G., Favaloro, E.J., Plebani, M. In Vitro and In Vivo Hemolysis - An
Unresolved Dispute in Laboratory Medicine; Germany: Walter de Gruyter GmbH, 2012.

(9)

Shih, AW., Mcfarlane, A., Verhovsek, M. Haptoglobin Testing in Hemolysis: Measurement
and Interpretation. Am. J. Hematol. 2014. 89(4), 443-7.

(10)

Marchand, A., Galen, R. S., Van Lente, F. The Predictive Value of Serum Haptoglobin in
Hemolytic Disease. JAMA. 1980, 243(19), 1909-11.

(11)

Kormoczi, G.F., Saemann, M.D., Buchta, C., Peck-Radosavljevic, M., Mayr, W.R.,
Schwartz, D.W.M., Dunkler, D., Spitzauer, S., Panzer, S. Influence of Clinical Factors on
the Haemolysis Marker Haptoglobin. Eur. J. Clin. Invest. 2006, 36(3), 202-9.

(12)

Howanitz, P. J., Lehman, C. M., Jones, B. A., Meier, F. A., Horowitz, G. L. Clinical
Laboratory Quality Practices When Hemolysis Occurs. Arch. Pathol. Lab. Med. 2015,
139(7), 901-6.

(13)

Koseoglu, M., Hur, A., Atay, A., Cuhadar, S. Effects of Hemolysis Interference on Routine
Biochemistry Parameters. Biochem. Medica. 2011, 21(1), 79-85.

(14)

Sahu, A., Sawant, S., Mamgain, H., Krishna, C. M. Raman Spectroscopy of Serum: An
Exploratory Study for Detection of Oral Cancers. Analyst 2013, 138, 4161–4174.

(15)

Blat, A.; Wiercigroch, E.; Smeda, M.; Wislocka, A.; Chlopicki, S.; Malek, K. Fourier
Transform Infrared Spectroscopic Signature of Blood Plasma in the Progression of Breast
Cancer with Simultaneous Metastasis to Lungs. J. Biophotonics 2019, 12(10), e201900067.

(16)

González-Solís, J. L.; Martínez-Espinosa, J. C.; Torres-González, L. A.; Aguilar-Lemarroy,
A.; Jave-Suárez, L. F.; Palomares-Anda, P. Cervical Cancer Detection Based on Serum
Sample Raman Spectroscopy. Lasers Med. Sci. 2014, 29 (3), 979–985.

(17)

Medipally, D. K. R.; Maguire, A.; Bryant, J.; Armstrong, J.; Dunne, M.; Finn, M.; Lyng, F.
M.; Meade, A. D. Development of a High Throughput (HT) Raman Spectroscopy Method
for Rapid Screening of Liquid Blood Plasma from Prostate Cancer Patients. Analyst 2017,
142 (8), 1216–1226.

(18)

Dinesh K.R. Medipally, Thi Nguyet Que Nguyen, Jane Bryant, Valérie Untereiner, Ganesh
D. Sockalingum, Daniel Cullen, Emma Noone, Shirley Bradshaw, Marie Finn, Mary
Dunne, Aoife M. Shannon, John Armstrong, F. M. L. and A. D. M. Monitoring
Radiotherapeutic Response in Prostate Cancer Patients Using High Throughput FTIR
Spectroscopy of Liquid Biopsies. Cancers (Basel). 2019, 11 (7), 925.

(19)

Helm, D.; Labischinski, H.; Naumann, D. Elaboration of a Procedure for Identification of
Bacteria Using Fourier-Transform IR Spectral Libraries: A Stepwise Correlation Approach.
J. Microbiol. Methods. 1991, 14(2), 127-142.

(20)

Lacombe, C.; Untereiner, V.; Gobinet, C.; Zater, M.; Sockalingum, G. D.; Garnotel, R.
Rapid Screening of Classic Galactosemia Patients: A Proof-of-Concept Study Using HighThroughput FTIR Analysis of Plasma. Analyst 2015, 140 (7), 2280–2286.

(21)

Yucel, D.; Dalva, K. Effect of in Vitro Hemolysis on 25 Common Biochemical Tests. Clin.
Chem. 1992, 38(4), 575-7.

(22)

Jones, A. M.; Honour, J. W. Unusual Results from Immunoassays and the Role of the
Clinical Endocrinologist. Clin. Endocrinol. (Oxf). 2006, 64(3):234-44.

(23)

Kirschner, M. B.; Edelman, J. J. B.; Kao, S. C. H.; Vallely, M. P.; Van Zandwijk, N.; Reid,
G. The Impact of Hemolysis on Cell-Free MicroRNA Biomarkers. Front. Genet. 2013, 24,
4, 94.

(24)

Opus 5 Reference Manual; Bruker OPTIK GmbH, 2004.

(25)

Savitzky, A.; Golay, M. J. E. Smoothing and Differentiation of Data by Simplified Least
Squares Procedures. Anal. Chem. 1964, 36 (8), 1627-1639.

(26)

Maguire, A.; Vegacarrascal, I.; White, L.; Mcclean, B.; Howe, O.; Lyng, F. M.; Meade, A.
D. Analyses of Ionizing Radiation Effects In Vitro in Peripheral Blood Lymphocytes with
Raman Spectroscopy. Radiat. Res. 2015, 183 (4), 407–416.

(27)

Choquette SJ, Etz ES, Hurst WS, Blackburn DH, L. S. Relative Intensity Correction of
Raman Spectrometers: NIST SRMs 2241 through 2243 for 785 Nm, 532 Nm, and 488
Nm/514.5 Nm Excitation. Appl. Spectrosc. 2007, 61 (2), 117–129.

(28)

Notingher, I.; Jell, G.; Notingher, P. L.; Bisson, I.; Polak, J. M. P.; Hench, L. L. Raman
Spectroscopy: Potential Tool for in Situ Characterization of Bone Cell Differentiation. Key
Eng. Mater. 2005, 284-286, 545-548.

(29)

Wu, Y.; Dong, Y.; Jiang, J.; Li, H.; Zhu, T.; Chen, S. Evaluation of the Bone-Ligament and
Tendon Insertions Based on Raman Spectrum and Its PCA and CLS Analysis. Sci. Rep.
2017, 7, 38706.

(30)

Stanimirovic, O.; Boelens, H. F. M.; Mank, A. J. G.; Hoefsloot, H. C. J.; Smilde, A. K.
Profiling of Liquid Crystal Displays with Raman Spectroscopy: Preprocessing of Spectra.
Appl. Spectrosc. 2005, 59(3), 267-74.

(31)

Nikolac, N. Lipemia: Causes, Interference Mechanisms, Detection and Management.
Biochemia Medica. 2014, 4(1), 57–67.

(32)

Dimeski, G.; Mollee, P.; Carter, A. Increased Lipid Concentration Is Associated with
Increased Hemolysis. Clinical Chemistry. 2005, 51(12), 2425.

(33)

Staniszewska-Slezak, E.; Fedorowicz, A.; Kramkowski, K.; Leszczynska, A.; Chlopicki, S.;
Baranska, M.; Malek, K. Plasma Biomarkers of Pulmonary Hypertension Identified by
Fourier Transform Infrared Spectroscopy and Principal Component Analysis. Analyst.
2015, 140(7), 2273-9.

(34)

Bonnier, F.; Baker, M. J.; Byrne, H. J. Vibrational Spectroscopic Analysis of Body Fluids:
Avoiding Molecular Contamination Using Centrifugal Filtration. Anal. Methods. 2014,
6(14), 5155-5160.

(35)

Maziak, D. E.; Do, M. T.; Shamji, F. M.; Sundaresan, S. R.; Perkins, D. G.; Wong, P. T.
Fourier-Transform Infrared Spectroscopic Study of Characteristic Molecular Structure in
Cancer Cells of Esophagus: An Exploratory Study. Cancer Detect. Prev. 2007, 31(3), 24453.

(36)

Gonzalez-Solís, J. L.; Martínez-Espinosa, J. C.; Salgado-Román, J. M.; Palomares-Anda,
P. Monitoring of Chemotherapy Leukemia Treatment Using Raman Spectroscopy and
Principal Component Analysis. Lasers Med. Sci. 2014, 29(3), 1241-9.

(37)

Movasaghi, Z.; Rehman, S.; Rehman, I. U. Raman Spectroscopy of Biological Tissues.
Applied Spectroscopy Reviews. 2007, 42(5), 493-541.

(38)

Borges, R. de C. F.; Navarro, R. S.; Giana, H. E.; Tavares, F. G.; Fernandes, A. B.; Silveira,
L. Detecting Alterations of Glucose and Lipid Components in Human Serum by NearInfrared Raman Spectroscopy. Rev. Bras. Eng. Biomed. 2015, 31(2), 160-168.

(39)

Takada, K.; Nasu, H.; Hibi, N.; Tsukada, Y.; Shibasaki, T.; Fujise, K.; Fujimuro, M.;
Sawada, H.; Yokosawa, H.; Ohkawa, K. Serum Concentrations of Free Ubiquitin and
Multiubiquitin Chains. Clin. Chem. 1997, 43(7), 1188-95.

(40)

Lippi, G.; Salvagno, G. L.; Montagnana, M.; Brocco, G.; Guidi, G. C. Influence of
Hemolysis on Routine Clinical Chemistry Testing. Clin. Chem. Lab. Med. 2006, 44(3), 3116.

(41)

Wei, J.; Zhao, J.; Schrott, V.; Zhang, Y.; Gladwin, M.; Bullock, G.; Zhao, Y. Red Blood

Cells Store and Release Interleukin-33. J. Investig. Med. 2015. 63(6), 806-10.

Tables

Table 1: Factors causing in vitro haemolysis [2].
During specimen collection

After Specimen collection

Strong aspiration while puncturing superficial Vigorous shaking of collected sample
veins
Aspiration with large needles causes higher Centrifugation of sample before completion of
haemolysis because of an increase in the flow- coagulation
rate, flow speed and turbulence.
Partial blockage of a venous or arterial catheter Centrifugation of partially coagulated samples
causes strong aspiration of the sample collected from patients on anticoagulants
with a syringe.
Specimen collection and subsequent splitting Positive or negative pressure in sample
into multiple tubes with a syringe.

collection tube
Dilution of blood with hypotonic solutions
Freeze thawing of whole blood
Storage or transportation of collected specimen
over several days at ambient temperatures

Table 2: Clinical characteristics of prostate cancer patients used in the study.

Number of subjects
Sex
Age (Years)
Mean
Median
Range
PSA (ng/ml)
Mean
Median
Range
T stage
T2
T3
Gleason score
7
8
9

Non-haemolysed

Mildly-haemolysed

Moderately-haemolysed

12
M

10
M

08
M

70.4
69.5
58 - 79

67.1
67
58 - 76

74.1
74
70 - 79

14.38
10.95
1.55 – 40.04

17.9
7.57
4 – 62

13.7
9.8
6.8 – 26.5

04 (33.3%)
08 (66.6%)

03 (30%)
07 (70%)

01 (12.5%)
07 (87.5%)

04 (33.3%)
06 (50%)
02 (16.6%)

04 (40%)
04 (40%)
02 (20%)

04 (50%)
02 (25%)
02 (25%)

Table 3: Pure molecular reference species used in haemolysis study
Category

Pure components

Protein and related
compounds

Apolipoprotein E4, Albumin, Haemoglobin
Interleukin-6, Interleukin-8 and Ubiquitin
Arachidonic acid, Cholesterol, Ceramide
Linolenic acid, Linoleic acid,
Oleic acid, Triglyceride, polyunsaturated fatty acid
(PUFA),

Lipids and Fatty acids

Sphingomyelin,
phosphatidylcholine, phosphatidylethanolamine,
phosphatidylserine, prostaglandin E1,
phosphatidylinositol

Nucleic acids and
related compounds
Metabolism and others

DNA, RNA, Thymidine
Glucose, Glycogen, Creatinine, Uric acid, Urea,
Insulin and β-carotene

Figures

Figure 1: Mean and standard deviation of instrument response corrected and pre-processed liquid
plasma Raman spectrum.

Figure 2: Three different types of liquid plasma samples in plasma biobank.

Figure 3: UV-VIS absorption spectrum of oxyhaemoglobin

Figure 4: Mean and standard deviation of FTIR absorption spectrum of haemoglobin.

A.

B.

C.

Figure 5: Mean and standard deviation Raman spectrum of (A) haemoglobin standard (B) diluted
haemoglobin standard and (C) haemoglobin isolated from blood.

Figure 6: Mean FTIR spectra of non-haemolysed, mildly haemolysed and moderately haemolysed
plasma samples.

Figure 7: Difference FTIR spectra of non-haemolysed and haemolysed plasma groups. Difference
spectra were computed by subtracting the mean FTIR spectra of haemolysed plasma from the mean
FTIR spectra of non-haemolysed spectra.

Figure 8: Mean Raman spectra of non-haemolysed, mildly-haemolysed and moderatelyhaemolysed plasma samples.

Figure 9: Difference Raman spectra of non-haemolysed and haemolysed plasma groups.
Difference spectra were computed by subtracting the mean Raman spectra of haemolysed plasma
from the mean Raman spectra of non-haemolysed spectra.

A.

B.

Figure 10: PCA for FTIR spectra of non-haemolysed, mildly-haemolysed and moderatelyhaemolysed plasma samples. (A) Score plots are shown for patients at non-haemolysed plasma
(blue), mildly-hemolysed plasma (red), and moderately-hemolysed plasma (yellow (B) PC-1 and
PC-2 loading plots for regions 800 – 1800 cm-1 and 2800 – 3100 cm-1. Covariance ellipse (95%
confidence) are shown for each class.

A.

B.

Figure 11: PCA for Raman spectra of non-haemolysed, mildly-haemolysed and moderatelyhaemolysed plasma samples. (A) Score plots are shown for patients at non-haemolysed plasma
(blue), mildly-hemolysed plasma (red), and moderately-hemolysed plasma (yellow (B) PC-1 and
PC-2 loading plots for regions 600 – 1800 cm-1. Covariance ellipse (95% confidence) are shown
for each class.

Figure 12: Relative concentrations of pure molecular reference species from least squares fit of
FTIR spectra of non-haemolysed and haemolysed prostate cancer plasma samples. Error bars
represent the standard error. Significance shown by (*,
p≤0.05, p≤0.01 and p≤0.001 respectively.

**,

and

***)

indicates the significance of

Figure 13: Relative concentrations of pure molecular reference species from least squares fit of
Raman spectra of non-haemolysed and haemolysed prostate cancer plasma samples. Error bars
represent the standard error. Significance shown by (*,
p≤0.05, p≤0.01 and p≤0.001 respectively.

**,

and

***)

indicates the significance of

Figure 14: Mean Raman spectra of non-haemolysed and in vitro haemolysed plasma samples.

Figure 15: PCA scatter plot for Raman spectra of non-haemolysed and in vitro haemolysed plasma
samples. Covariance ellipse (95% confidence) are shown for each class.

Figure 16: Relative concentrations of pure molecular reference species from least squares fit of
Raman spectra of non-haemolysed and in vitro haemolysed plasma samples. Error bars represent
the standard error. Significance shown by (*,
p≤0.01 and p≤0.001 respectively.

**,

and

***)

indicates the significance of p≤0.05,

Supplementary material
Table S1: Details of pure molecular reference species used in this study.

SN

Component name

Company

Product number

State

Protein and related species
1

Albumin

Sigma Aldrich

A7030

Powder

2

Haemoglobin

Sigma Aldrich

H7379

Powder

3

Interleukin-6

Sigma Aldrich

I13965

Powder

4

Interleukin-8

Sigma Aldrich

I-1645

Powder

5

Ubiquitin

Sigma Aldrich

U6253

Powder

6

Apolipoprotein E4

Sigma Aldrich

A3234

Powder

Nucleic acids and nucleobases
7

RNA

Sigma Aldrich

R6750

Powder

8

DNA

Sigma Aldrich

D-1626

Powder

9

Thymidine

Sigma Aldrich

T1895

Powder

Lipids, fatty acids and related species
10

Ceramide

Sigma Aldrich

22244

Powder

11

Cholesterol

Sigma Aldrich

C3045

Powder

12

Linoleic acid

Sigma Aldrich

L1376

Liquid

13

Linolenic acid

Sigma Aldrich

L2376

Liquid

14

Oleic acid

Sigma Aldrich

O1008

Liquid

15

L-α-Phosphatidylcholine

Sigma Aldrich

L4129

Powder

16

L-α-Phosphatidylserine

Avanti

8703363C

Liquid

17

L-α-Phosphatidylinositol

Sigma Aldrich

P-6636

Powder

18

L-α-Phosphatidylethanolamine

Sigma Aldrich

P-7693

Powder

19

Prostaglandin E1

Sigma Aldrich

P5515

Liquid

20

PUFA

SUPELCO

47015-U

Liquid

21

Sphingomyelin

Sigma Aldrich

S0756

Powder

22

Triglyceride mixture

Sigma Aldrich

17811-1AMP

Powder

23

Arachidonic acid

Sigma Aldrich

10931

Liquid

Other metabolites
24

β-Carotene

Sigma Aldrich

C4582

Powder

25

Urea

Sigma Aldrich

U4884

Powder

26

Uric acid

Sigma Aldrich

U2625

Powder

27

Creatinine

Sigma Aldrich

C4255

Powder

28

Glucose

Sigma Aldrich

G8270

Powder

29

Glycogen

Sigma Aldrich

G0885

Powder

30

Insulin

Sigma Aldrich

I2643

Powder

Figure S1: Raman spectrum of pure molecular reference species.

Figure S2: FTIR spectrum of pure molecular reference species.

